Clinical Trial Update: Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy [Phase 2]

View source ↗

Summary

A Phase 2 exploratory clinical study is evaluating camrelizumab plus risedronate and chemotherapy for triple-negative breast cancer, focusing on mechanisms and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Chemotherapy (unspecified agents)
• risedronate (risedronate)

Snippet

Sponsor: Harbin Medical University | Conditions: Breast Cancer Triple Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING